These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7622828)

  • 41. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
    Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
    Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
    Johnson DA; Pasterski G; Ludlow JM; Street K; Taylor RD
    Acta Psychiatr Scand; 1983 May; 67(5):339-52. PubMed ID: 6135298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early intervention in patients at ultra high risk of psychosis: benefits and risks.
    de Koning MB; Bloemen OJ; van Amelsvoort TA; Becker HE; Nieman DH; van der Gaag M; Linszen DH
    Acta Psychiatr Scand; 2009 Jun; 119(6):426-42. PubMed ID: 19392813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brief intermittent neuroleptic prophylaxis for selected schizophrenic out-patients.
    McClelland HA; Harrison G; Soni SD
    Br J Psychiatry; 1989 Nov; 155():702-6. PubMed ID: 2575424
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
    Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
    Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors influencing relapse in the long-term course of schizophrenia.
    Ayuso-Gutiérrez JL; del Río Vega JM
    Schizophr Res; 1997 Dec; 28(2-3):199-206. PubMed ID: 9468354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compliance, quality assurance and standards for relapse prevention in schizophrenia.
    Kissling W
    Acta Psychiatr Scand Suppl; 1994; 382():16-24. PubMed ID: 7916524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
    Csernansky JG; Mahmoud R; Brenner R;
    N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.
    Essali A; Deirawan H; Soares-Weiser K; Adams CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD000206. PubMed ID: 22071797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse.
    Hirsch S; Bowen J; Emami J; Cramer P; Jolley A; Haw C; Dickinson M
    Br J Psychiatry; 1996 Jan; 168(1):49-56. PubMed ID: 8770428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How high is the relapse rate in schizophrenia?
    Johnstone EC; Geddes J
    Acta Psychiatr Scand Suppl; 1994; 382():6-10. PubMed ID: 7916528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Discontinuation of neuroleptic treatment in patients with schizophrenia].
    Alagille M; Blondiaux I; Ginestet D
    Encephale; 1990; 16(2):125-31. PubMed ID: 1972052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Strategies of long-term medication in schizophrenia].
    Gaebel W
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S113-9. PubMed ID: 11533861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.